Search clinical trials for: Somatostatin receptor positive tumour

Total 29363 results

Sociedad Española de Medicina Nuclear e Imagen...

Recruiting

Spanish Series of Patients Treated With the Radionuclide Lutetium177 (SEPTRALU)

Digestive System Diseases | Neoplasms | Neoplasms by Histologic Type | Neoplasms by Site | Endocrine System Diseases | Stomach Neoplasms | Gastrointestinal Neoplasms | Digestive System Neoplasms | Neoplasms, Germ Cell and Embryonal | Endocrine Gland Neoplasms | Neuroectodermal Tumors | Neoplasms, Nerve Tissue | Intestinal Diseases and other conditions

Spain
Vastra Gotaland Region
Advanced Accelerator Applications

Active, not recruiting

177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours (LuPARP)

Thymoma | Neuroendocrine Tumors | Mesothelioma | Clinical Trial, Phase I

Sweden
Lawson Health Research Institute

Active, not recruiting

An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours

Neuroendocrine Carcinoma

Canada
Advanced Accelerator Applications

Completed

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours (NETTER-1)

Carcinoid Tumor of the Small Bowel | Neuroendocrine Tumour

United States, United Kingdom, Italy, Belgium, France, Germany, Portugal, Spain
ITM Solucin GmbH

Not yet recruiting

Phase I Trial to Determine the Dose and Evaluate the PK of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors (KinLET)

Lymphoma | CNS Tumor | Solid Tumor, Childhood | Somatostatin Receptor Positive | NET
National Cancer Institute (NCI)

Not yet recruiting

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

Pheochromocytoma | Somatostatin Receptor Positive | Paragangliomas | Gastrointestinal Neuroendocrine Tumors

United States
Juan LI, MD

Recruiting

To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Non Small Cell Lung Cancer | EGFR Exon 20 Insertion Mutation

China
University of Wisconsin, Madison

Not yet recruiting

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

Neuroendocrine Tumors | Somatostatin Receptor-positive Neuroendocrine Tumor

United States
Grupo Espanol de Tumores Neuroendocrinos
MFAR; ITM Oncologics GmbH

Recruiting

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. (LEVEL)

Thymus Neoplasms | Neuroendocrine Tumors | Lung Neuroendocrine Neoplasm

Spain, Italy, France
Peking University

Not yet recruiting

Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors

Neuroendocrine Tumors

China
Cancer Research UK
Royal Marsden NHS Foundation Trust; Hoffmann-La Roche; University of Manchester; University of Birmingham

Recruiting

DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers (DETERMINE)

Neoplasms by Histologic Type | Lymphoma | Lymphoproliferative Disorders | Neoplasms by Site | Renal Cell Carcinoma | Cancer | Solid Tumor | Anaplastic Large Cell Lymphoma | Neuroblastoma | Malignant Neoplasm | Haematological Malignancy

United Kingdom
University of Utah
National Cancer Institute (NCI); MultiFunctional Imaging LLC

Recruiting

Dual-Tracer Theranostic PET

Prostate Cancer | Neuroendocrine Tumors

United States
University Hospital, Basel, Switzerland
Swiss National Science Foundation; Paul Scherrer Institute (PSI)

Recruiting

Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3) (Beta plus)

Neuroendocrine Neoplasia's (NENs) | Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

Switzerland
University Hospital, Basel, Switzerland
Swiss Cancer League

Recruiting

Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide (PROMENADE)

Meningioma

Switzerland
Royal Marsden NHS Foundation Trust
Pfizer; AstraZeneca; Institute of Cancer Research, United Kingdom; UNICANCER; Gustave... and other collaborators

Recruiting

A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer (TRAK-ER)

HER2-negative Breast Cancer | ER+ Breast Cancer

United Kingdom, France
University of Alberta

Recruiting

68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors

Neuroendocrine Tumors

Canada
Allist Pharmaceuticals, Inc.

Not yet recruiting

To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (FORWARD)

Non-small Cell Lung Carcinoma
University Hospital, Bordeaux
Advanced Accelerator Applications

Recruiting

Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases (LUTARTERIAL)

Neuroendocrine Tumor | Liver Metastases | Neuroendocrine Gastroenteropancreatic Tumour

France
National Cancer Institute (NCI)

Recruiting

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Locally Advanced Lung Neuroendocrine Neoplasm | Lung Neuroendocrine Neoplasm | Metastatic Lung Neuroendocrine Neoplasm | Recurrent Lung Neuroendocrine Neoplasm | Unresectable Lung Neuroendocrine Neoplasm | Advanced Lung Neuroendocrine Tumor | Functioning Lung Neuroendocrine Tumor | Lung Neuroendocrine... and other conditions

United States
Weill Medical College of Cornell University
Novartis Pharmaceuticals

Recruiting

68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors. (DOMINO-START)

Pituitary Adenoma | Medulloblastoma | Meningioma | Esthesioneuroblastoma | Paraganglioma | CNS Tumors | Hemangioblastoma

United States
AHS Cancer Control Alberta

Recruiting

A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use

Neuroendocrine Tumors

Canada
AstraZeneca

Active, not recruiting

A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. (FALCON)

Hormone Receptor Positive Breast Cancer

Canada, Spain, United States, Romania, Taiwan, Italy, Brazil, Peru, Russian Federation, China, Czechia, Ukraine, South Africa, Japan, Poland, Mexico, United Kingdom, Argentina, Slovakia, Turkey
Novartis Pharmaceuticals

Active, not recruiting

A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea

Somatostatin Receptor-positive GEP-NET

Korea, Republic of
Novartis Pharmaceuticals

Active, not recruiting

LUTATHERA Injection General Use Result Survey

Somatostatin Receptor-positive Neuroendocrine Tumor

Japan
Providence Health & Services
Exelixis; Advanced Accelerator Applications SA

Active, not recruiting

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Neuroendocrine Tumors

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer

HR-positive, HER2-negative Breast Neoplasms

China
Royal Marsden NHS Foundation Trust
Pfizer; Breast Cancer Now

Active, not recruiting

Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours (ROLo)

Gastric Cancer | Triple Negative Breast Cancer | Lobular Breast Carcinoma | CDH1 Gene Mutation

United Kingdom
AstraZeneca

Completed

Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours (AURA2)

Non Small Cell Lung Cancer

Italy, United States, Canada, Korea, Republic of, Japan, Taiwan, Hong Kong, Spain
Jagiellonian University
Medical University Innsbruck; University Medical Centre Ljubljana; University... and other collaborators

Completed

Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine Neoplasms (TECANT)

Neuroendocrine Tumors

Austria, Poland, Slovenia
University Health Network, Toronto
Cancer Care Ontario; Ozmosis Research Inc.; Canadian Molecular Imaging Probe...

Active, not recruiting

Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

Neuroendocrine Tumors

Canada
Radio Isotope Therapy of America
Excel Diagnostics and Nuclear Oncology Center; Radiomedix, Inc.

Completed

68-Ga-DOTATATE PET-CT Scan for Diagnosis of Primary and Metastatic Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)

Neuroendocrine Carcinoma

United States
Spanish Breast Cancer Research Group
Pfizer

Completed

Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients

Breast Cancer

Spain
British Columbia Cancer Agency

Withdrawn

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

Neuroendocrine Tumors | Carcinoid Tumor | Gastrinoma | Insulinoma | Vipoma | Gastroenteropancreatic Neuroendocrine Tumor | Pulmonary Carcinoid Tumor

Canada
Radiomedix, Inc.

Completed

Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE

Neuroendocrine Tumors

United States
Ipsen

Terminated

Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2) (SSTR2+)

Small Cell Lung Cancer and Breast Cancer

United States, Austria, France, Switzerland, Germany, United Kingdom, Belgium
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

Metastatic Adrenal Gland Pheochromocytoma | Stage III Thyroid Gland Medullary Carcinoma AJCC v8 | Stage IV Thyroid Gland Medullary Carcinoma AJCC v8 | Locally Advanced Adrenal Gland Pheochromocytoma | Locally Advanced Paraganglioma | Metastatic Paraganglioma | Metastatic Parathyroid Gland Carcinoma and other conditions

United States
GlaxoSmithKline

Completed

Immuno Positron Emission Tomography Study of GSK2849330 in Subjects With Human Epidermal Growth Factor Receptor 3-Positive Solid Tumors

Neoplasms | Cancer

Netherlands
Istituto Scientifico Romagnolo per lo Studio e...

Terminated

Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas (itTRIOlym)

Recurrent Disease | DLBCL | MCL

Italy
Andrei Iagaru

No longer available

68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors

Carcinoid Tumors | Islet Cell (Pancreatic NET) | Other Neuroendocrine Tumors

United States
Lale Kostakoglu

Terminated

68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)

Neuroendocrine Tumors | Carcinoid Tumors

United States
National University Hospital, Singapore
Tan Tock Seng Hospital

Unknown

Evaluation of Somatostatin Receptor Imaging Using PET/MRI as a Novel Approach to Detecting Pathology in Pulmonary TB

Tuberculosis

Singapore
Emory University
Novartis

Terminated

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

Mucositis | Stage III Renal Cell Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Gastrinoma | Glucagonoma | Insulinoma | Pancreatic Polypeptide Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Stage IIIC Breast... and other conditions

United States
Miglani, Anjali
Department of Indian Systems of Medicine and Homeopathy

Completed

Efficacy of Azadirachta Indica (Homoeopathic Medicine) in Treatment of Acne Vulgaris

Acne Vulgaris

India
Dana-Farber Cancer Institute
Johns Hopkins University; Translational Breast Cancer Research Consortium

Not yet recruiting

The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Breast Cancer | HER2-positive Breast Cancer | Stage IV Breast Cancer | Breast Cancer Female | Breast Cancer Metastatic | Estrogen Receptor-positive Breast Cancer

United States
Jules Bordet Institute
RayzeBio, Inc.

Not yet recruiting

A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors (AcTRESS)

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Multiple Myeloma Progression

Belgium
M.D. Anderson Cancer Center

Not yet recruiting

Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)

Hormone Receptor-positive Human Epidermal Growth Factor 2-negative | Metastatic Invasive LObular Carcinoma

United States
Mayo Clinic

Not yet recruiting

Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage 0 Breast Cancer AJCC v8 | Breast Adenocarcinoma | Estrogen Receptor-Positive Breast Carcinoma | Progesterone Receptor-Positive Breast Carcinoma

United States
Takeda

Recruiting

A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors

Ovarian Cancer | Solid Tumors

Japan
Mayo Clinic

Recruiting

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients

Metastatic Breast Cancer | HER2-negative Breast Cancer | Hormone-receptor-positive Breast Cancer

United States
MedSIR
Stemline Therapeutics, Inc.

Not yet recruiting

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. (ADELA)

Advanced Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | ESR1 Gene Mutation

Search clinical trials for: Somatostatin receptor positive tumour

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations